VarmX

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. VarmX's mission is to develop and manufacture therapeutic proteins to immediately restore blood clotting in bleeding patients. The main product in VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X that can immediately restore blood clotting in the presence of direct factor Xa anticoagulants (DOACs) such as rivaroxaban, apixaban, and edoxaban.